TITLE

Vilazodone approved for major depression

AUTHOR(S)
Traynor, Kate
PUB. DATE
March 2011
SOURCE
American Journal of Health-System Pharmacy;3/1/2011, Vol. 68 Issue 5, p366
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports the approval of vilazodone hydrochloride oral tablets, to be marketed as 'Viibryd', for the treatment of major depressive disorders, as announced by Clinical Data Inc. of Newton, Massachusetts. It discusses the Food and Drug Administration (FDA) approved labeling for the drug, and its warning against pediatric use due to an increased risk of suicidal thinking. The article also reports the drug's recommended starting dosage, efficacy and packaging specifications.
ACCESSION #
58638844

 

Related Articles

  • Drug for Depression Goes to FDA for Review.  // Journal of Psychosocial Nursing & Mental Health Services;Feb2013, Vol. 51 Issue 2, p45 

    No abstract available.

  • FDA Actions. Elliott, William T. // Neurology Alert;Mar2011 Primary Care, p2 

    The article presents updates on the actions of the U.S. Food and Drug Administration (FDA) as of March 2011, including its approval of vilazodone hydrocholoride for the treatment of depression in adults, its move to limit the amount of acetaminophen in combination prescription pain medications,...

  • Seroquel XR OK'd for MDD.  // Monthly Prescribing Reference;Jan2010, Vol. 26 Issue 1, pA11 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the drug Seroquel XR from AstraZeneca PLC as adjunctive treatment to antidepressants in adults with major depressive disorder (MDD).

  • News from the FDA. Pennachio, Dorothy L. // Patient Care;Nov2003, Vol. 37 Issue 11, p11 

    Reports on the approval of several drugs by the U.S. Food and Drug Administration in November 2003. Wellbutrin XL for treating major depressive disorder in old patients; Paxil CR for treating pre-menstrual dysphoric disorder; Cubicin for treating skin structure infections; Zonegran for treating...

  • Eli Lilly: Cymbalta approved for treatment of anxiety.  // PharmaWatch: CNS;Apr2007, Vol. 6 Issue 4, p9 

    The article reports on the approval of Eli Lilly's Cymbalta, a serotonin and norepinephrine reuptake inhibitor for the treatment of patients with generalized anxiety disorder (GAD), by the U.S. Food and Drug Administration. Cymbalta is a class of drugs that is primarily indicated for the...

  • New molecular entities.  // Formulary;Sep2004, Vol. 39 Issue 9, p428 

    Reports on the United States Food and Drug Administration's approval of antidepressant Duloxetine for the treatment of major depressive disorder. Efficacy; Safety; Dosing.

  • FDA actions in brief.  // Formulary;May2009, Vol. 44 Issue 5, p135 

    The article offers news briefs related to the approved drugs by the U.S. Food and Drug Administration. Aremether, manufactured by Novartis and Coartem, has been approved for the treatment of uncomplicated infections caused by Plasmodium falciparum. Escitalopram, produced by Lexapro and Forest,...

  • FDA APPROVES DESVENLAFAXINE SUCCINATE FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER. J. C. // Primary Psychiatry;May2008, Vol. 15 Issue 5, p25 

    The article reports on the approval of desvenlafaxine succinate, a serotonin norepinephrine reuptake inhibitor, by the U.S. Food and Drug Administration to treat adult patients with major depressive disorder (MDD). Accordingly, its efficacy was established through four, 8-week randomized,...

  • FDA Drug Approval to Change its Ways? Elliott, William T. // Clinical Cardiology Alert;May2008 Pharmacology Watch, Vol. 27, p1 

    The article reports on the recent actions by the U.S. Food and Drug Administration in 2008. The agency has issued an early communication regarding Boehringer Ingelheim's tiotropium inhaler due to its reported association with an increased risk of stroke. Also, the FDA approved the desvenlafaxine...

  • FDA Actions. Elliott, William T. // Clinical Cardiology Alert;Apr2007 Pharmacology Watch, p2 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to duloxetine for the treatment of generalized anxiety disorder. The FDA gave its approval of the drug for the treatment of major depressive disorder in the management of diabetic peripheral neuropathic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics